Nucl Med Mol Imaging.  2019 Jun;53(3):189-198. 10.1007/s13139-019-00587-w.

Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors

Affiliations
  • 1Centurion Biopharma Corporation/CytRx Drug Discovery Branch, Engesserstr. 4, 79108 Freiburg, Germany. fkratz@centurionbiopharma.com

Abstract

PURPOSE
The purpose of this study was to investigate the albumin-binding compound 111In-C4-DTPA as an imaging agent for the detection of endogenous albumin accumulation in tumors.
METHODS
111In-C4-DTPA was injected in healthy nude mice for pharmacokinetic and biodistribution studies (10 min, 1, 6, 24, and 48 h, n = 4) and subsequently in tumor-bearing mice for single-photon emission computed tomography/X-ray-computed tomography (SPECT/CT) imaging studies. Four different human tumor xenograft models (LXFL529, OVXF899, MAXFTN401, and CXF2081) were implanted subcutaneously unilaterally or bilaterally (n = 4-8). After intravenous administration of 111In-C4-DTPA, SPECT/CT images were collected over 72 h at 4-6 time points. Additionally, gamma counting was performed for the blood, plasma, lungs, heart, liver, spleen, kidneys, muscle, and tumors at 72 h post-injection.
RESULTS
111In-C4-DTPA bound rapidly to circulating albumin upon injection, and the radiolabeled albumin conjugate thus formed was stable in murine and human serum. SPECT/CT images demonstrated a time-dependent uptake with a maximum of 2.7-3.8% ID/cm3 in the tumors at approximately 24 h post-injection and mean tumor/muscle ratios in the range of 3.2-6.2 between 24 and 72 h post-injection. The kidneys and bladder were the predominant elimination organs. Gamma counting at 72 h post-injection showed 1.3-2.5% ID/g in the tumors and mean tumor/muscle ratios in the range of 4.9-9.4.
CONCLUSION
111In-C4-DTPA bound rapidly to circulating albumin upon injection and showed time-dependent uptake in the tumors demonstrating a potential for clinical application as a companion imaging diagnostic for albumin-binding anticancer drugs.

Keyword

Albumin; Drug carrier; Imaging agent; SPECT/CTimaging; Tumor accumulation; ¹¹¹In

MeSH Terms

Administration, Intravenous
Animals
Drug Carriers
Friends
Heart
Heterografts
Humans
Kidney
Liver
Lung
Mice
Mice, Nude
Plasma
Spleen
Urinary Bladder
Drug Carriers
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr